The chemical class termed SorCS3 Inhibitors represents a group of compounds meticulously designed to selectively target the molecular entity SorCS3. SorCS3, short for Sortilin-Related VPS10p Domain Containing Receptor 3, is a transmembrane protein belonging to the VPS10p domain receptor family. These receptors are involved in cellular processes such as protein trafficking, neurotrophic signaling, and modulation of intracellular pathways. Despite the recognition of SorCS3's significance in these processes, the specific functional roles and detailed interactions associated with SorCS3 remain subjects of active investigation within the field of molecular biology. Inhibitors within the SorCS3 Inhibitors class are intricately engineered molecules with the primary objective of modulating the activity or function of SorCS3, thereby inducing an inhibitory effect. Researchers in this field employ a multifaceted approach, integrating insights from structural biology, medicinal chemistry, and computational modeling to unravel the complex molecular interactions between the inhibitors and the target SorCS3.
Structurally, SorCS3 Inhibitors are characterized by specific molecular features designed to facilitate selective binding to SorCS3. This selectivity is essential to minimize unintended effects on other cellular components, ensuring a focused impact on the intended molecular target. The development of inhibitors within this chemical class involves a comprehensive exploration of structure-activity relationships, optimization of pharmacokinetic properties, and a deep understanding of the molecular mechanisms associated with SorCS3. As researchers delve deeper into the functional aspects of SorCS3 Inhibitors, the knowledge generated contributes not only to deciphering the specific roles of SorCS3 but also to advancing our broader comprehension of cellular processes and molecular regulation. The exploration of SorCS3 Inhibitors stands as a significant avenue for expanding fundamental knowledge in molecular pharmacology and cellular biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A cytidine analog that incorporates into DNA and RNA; it inhibits DNA methyltransferases leading to hypomethylation of DNA, which can downregulate gene expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor that can alter chromatin structure and gene expression, potentially reducing the transcription of SorCS3. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
A non-nucleoside DNA methyltransferase inhibitor, which may lead to DNA hypomethylation and potentially affect the expression of SorCS3. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
A benzamide histone deacetylase inhibitor that can alter gene expression by changing chromatin accessibility. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
An analog of 5-azacytidine that inhibits DNA methyltransferase, leading to DNA hypomethylation and potentially altered gene expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Another histone deacetylase inhibitor that can change the expression of many genes, possibly including SorCS3. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
A PARP inhibitor that, while used mainly for its effects on DNA repair, can also influence gene expression profiles. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
Disrupts the interaction between p53 and MDM2, leading to activation of p53 and affecting the expression of genes regulated by this tumor suppressor. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
A BET bromodomain inhibitor that affects the reading of acetylated histones, potentially downregulating transcription of certain genes. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
A chemotherapeutic agent that binds to G-C rich sequences in DNA, interfering with transcription factor binding and potentially downregulating gene expression. |